169 related articles for article (PubMed ID: 12691534)
1. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers.
Moulton HM; Hase MC; Smith KM; Iversen PL
Antisense Nucleic Acid Drug Dev; 2003 Feb; 13(1):31-43. PubMed ID: 12691534
[TBL] [Abstract][Full Text] [Related]
2. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.
Moulton HM; Nelson MH; Hatlevig SA; Reddy MT; Iversen PL
Bioconjug Chem; 2004; 15(2):290-9. PubMed ID: 15025524
[TBL] [Abstract][Full Text] [Related]
3. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
Ghosh C; Iversen PL
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
[TBL] [Abstract][Full Text] [Related]
4. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing.
Marshall NB; Oda SK; London CA; Moulton HM; Iversen PL; Kerkvliet NI; Mourich DV
J Immunol Methods; 2007 Aug; 325(1-2):114-26. PubMed ID: 17673254
[TBL] [Abstract][Full Text] [Related]
5. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity.
Nelson MH; Stein DA; Kroeker AD; Hatlevig SA; Iversen PL; Moulton HM
Bioconjug Chem; 2005; 16(4):959-66. PubMed ID: 16029037
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers.
Geller BL; Deere JD; Stein DA; Kroeker AD; Moulton HM; Iversen PL
Antimicrob Agents Chemother; 2003 Oct; 47(10):3233-9. PubMed ID: 14506035
[TBL] [Abstract][Full Text] [Related]
7. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
[TBL] [Abstract][Full Text] [Related]
8. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli.
Tilley LD; Mellbye BL; Puckett SE; Iversen PL; Geller BL
J Antimicrob Chemother; 2007 Jan; 59(1):66-73. PubMed ID: 17079242
[TBL] [Abstract][Full Text] [Related]
9. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues.
Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ
Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911
[TBL] [Abstract][Full Text] [Related]
10. Gene-specific effects of antisense phosphorodiamidate morpholino oligomer-peptide conjugates on Escherichia coli and Salmonella enterica serovar typhimurium in pure culture and in tissue culture.
Tilley LD; Hine OS; Kellogg JA; Hassinger JN; Weller DD; Iversen PL; Geller BL
Antimicrob Agents Chemother; 2006 Aug; 50(8):2789-96. PubMed ID: 16870773
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc.
Hudziak RM; Summerton J; Weller DD; Iversen PL
Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):163-76. PubMed ID: 10905553
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides.
Turner JJ; Arzumanov AA; Gait MJ
Nucleic Acids Res; 2005; 33(1):27-42. PubMed ID: 15640444
[TBL] [Abstract][Full Text] [Related]
13. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers.
Stein DA; Skilling DE; Iversen PL; Smith AW
Antisense Nucleic Acid Drug Dev; 2001 Oct; 11(5):317-25. PubMed ID: 11763348
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
16. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
17. Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.
Devi GR
Methods Mol Biol; 2009; 542():351-61. PubMed ID: 19565912
[TBL] [Abstract][Full Text] [Related]
18. Five-step process for screening antisense compounds for efficacy: gene target IL-12Rb2.
Marshall NB; Hauck LL; Mourich DV
Methods Mol Biol; 2011; 764():153-68. PubMed ID: 21748639
[TBL] [Abstract][Full Text] [Related]
19. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
20. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli.
Deere J; Iversen P; Geller BL
Antimicrob Agents Chemother; 2005 Jan; 49(1):249-55. PubMed ID: 15616302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
